ProShares UltraPro Short QQQ ETF vs Tempus AI — how do they compare? ProShares UltraPro Short QQQ ETF trades at $32.95 (market cap $2.23B), while Tempus AI trades at $70.93 (market cap $12.58B). The key difference: Tempus AI is far larger — about 5.6× ProShares UltraPro Short QQQ ETF's market cap, and Tempus AI is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro Short QQQ ETF for 12 Days and Tempus AI for 23 Days on average.
| SQQQ | TEM | |
|---|---|---|
Market Cap | $2.23B | $12.58B |
Volume | 60,436,012 | 7,444,569 |
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $89.43 | $96.39 |
52-Week Low | $31.83 | $41.55 |
Typical Hold Time | 12 Days | 23 Days |
Enterprise Value | — | $13.21B |
Signals from Pluang's Aura AI — not financial advice
SQQQ (ProShares UltraPro Short QQQ) trades at $33.37, up 4.02% today, reflecting its bearish positioning against the Nasdaq 100. Technical indicators show a predominantly bearish signal with moving averages indicating selling pressure, while oscillators remain neutral. The ETF serves as a leveraged short tool for hedging QQQ exposure, with recent news highlighting its strategic use in portfolio protection amid tech sector volatility.
The outlook for SQQQ remains tied to Nasdaq 100 performance, offering potential gains during market downturns but carrying high risk due to daily rebalancing and decay. Key risks include rapid market reversals and the structural challenges of leveraged inverse ETFs. Investor sentiment is cautious, with media coverage emphasizing its role as a hedging instrument rather than a long-term hold.
Tempus AI (TEM) trades at $69.28, down 1.44% today, with a bullish technical signal despite bearish moving averages. The company shows strong revenue growth (2026: $1.4B) but remains unprofitable with negative margins. Recent FDA clearance for ECG-MR AI product and ESMO Congress presentations highlight innovation momentum. Analyst consensus is strongly bullish with 64% buy ratings and $72.60 price target.
TEM offers growth potential in AI-driven healthcare diagnostics but carries significant execution risk due to persistent losses. The stock's high P/S ratio (8.61) reflects growth expectations, yet negative ROE (-67.44%) and insider selling warrant caution. Upside depends on profitability improvements and commercial adoption of new AI products.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →